Cart
sales@molnova.com
TNKS-2-IN-2
CAS No. 2719726-91-5
TNKS-2-IN-2( —— )
Catalog No. M37091 CAS No. 2719726-91-5
TNKS-2-IN-2 is a novel and potent TNKS2 selective inhibitor (IC50: 22 nM) with potential anti-tumour activity for studying colon cancer, lung cancer, and breast cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 240 | In Stock |
|
| 5MG | 376 | In Stock |
|
| 10MG | 534 | In Stock |
|
| 25MG | 821 | In Stock |
|
| 50MG | 1122 | In Stock |
|
| 100MG | 1485 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTNKS-2-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionTNKS-2-IN-2 is a novel and potent TNKS2 selective inhibitor (IC50: 22 nM) with potential anti-tumour activity for studying colon cancer, lung cancer, and breast cancer.
-
DescriptionTNKS-2-IN-2 is a potent and selective inhibitor of TNKS2 with an IC50 of 22 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
RecptorWnt/beta-catenin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2719726-91-5
-
Formula Weight473.48
-
Molecular FormulaC26H23N3O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=CC=C(C=C1)NC(=O)C2=CNC=3C=CC=CC3C2=O)C4=CC(OC)=C(OC)C(OC)=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhang X, et al. Design, synthesis, and biological activity evaluation of new tankyrase-2 directed inhibitors. Chem Biol Drug Des. 2023 Oct 10.?
molnova catalog
related products
-
TNIK-IN-7
TNIK-IN-7 is a potent and selective Traf2 and Nck interacting kinase (TNIK) inhibitor (IC50: 11 nM) with antitumor activity for studying signaling and proliferation in colorectal cancer cells.
-
β-catenin modulator ...
β-catenin modulator IIa-661 is a small molecule inhibitor of the Wnt pathway with antitumour activity.
-
DIF-3
DIF-3 is a chemical compound that acts by activating GSK-3β to facilitate the degradation of cyclin D1 and c-Myc, resulting in reduced expression levels of these proteins.
